Pivotal PYNNACLE phase 2 trial of rezatapopt in heavily pre-treated, advanced solid tumors with a TP53 Y220C mutation: Initial ovarian cancer analysis.

Key Points

This trial aims to assess the efficacy and safety of rezatapopt in patients with advanced ovarian cancer possessing a TP53 Y220C mutation.
Single-arm phase 2 trial
Evaluated patients with TP53 Y220C mutations
Administered rezatapopt 2000 mg once daily
Overall response rate was 46% in efficacy-evaluable patients with ovarian cancer
Median time to response was 1.3 months; duration of response was 8.0 months
Treatment-related adverse events were mostly Grade 1/2, with the most common being nausea (34%) and fatigue (23%)

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Evaluates overall response rate of rezatapopt in ovarian cancer, suggesting promising targeted therapy for specific mutation.

No takes yet. Share an insight, caveat, or question.

Tan et al. (2026) studied this question.

View at Publisher

Ask AI

Bookmark

Share